Advertisement
Gerresheimer AG has been listed in the Prime Standard of the FrankfurtStock Exchange since June 11, 2007 after one of the largest IPOs of the year,with a total issue volume in excess of EUR900 million. Already, on September6, 2007, Gerresheimer was included in the SDAX Index ahead of the normalscheduling process.
Advertisement
"Inclusion in the index confirms Gerresheimer's outstanding development.As an MDAX constituent our company is now even more attractive for nationalas well as international investors and attracts the attention of the capitalmarket to an increased degree," says Dr. Axel Herberg, CEO of Gerresheimer AG.
In the first nine months of the financial year 2008 (December 2007 toAugust 2008), sales increased markedly by 12.3 % to EUR783.4m (prior yearperiod: EUR697.4m). Operating results (adjusted EBITDA) to the end of Augustactually improved by 18.1 % to EUR146.9m (EUR124.4m). The adjusted EBITDAmargin was 18.8 %, a full percentage point higher than in the comparableperiod of the prior year.
About Gerresheimer
Gerresheimer employs more than 10,000 people in 40 locations in Europe,America and Asia. In the financial year 2007, worldwide sales totalledEUR958m. The product portfolio ranges from pharmaceutical vials made of glassand plastic through to complex drug-delivery systems for the pharma & lifescience industry. These include sterile syringes, inhalers and othersystem-based approaches for safe dosage and application of medications. TheGroup enjoys a leading position in markets which are characterised by hightechnical and regulatory barriers.Contact Press Burkhard Lingenberg Director Corporate PR & Marketing Telephone +49-211-6181-250 Telefax +49-211-6181-241 E-mail [email protected] Contact Investor Relations Anke Linnartz Director Corporate Investor Relations Telephone +49-211-6181-314 Telefax +49-211-6181-121 E-mail [email protected]
SOURCE Gerresheimer AG
